Fluctuations in blood composition that often arise from commonly used therapies among kidney disease patients are not an independent predictor of adverse outcomes for European hemodialysis patients, according to a new study. The results suggest that although hemoglobin variability is common in kidney disease patients, it does not appear to increase their likelihood of dying early.